^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AAT-008

    i
    Other names: RQ-00000008 (AAT-008), AAT-008, RQ-08
    Associations

    News

    Trials
    Company:
    AskAt, ImageneBio
    Drug class:
    PGE4 antagonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    Biological effects of prostaglandin E2-EP4 antagonist (AAT-008) in murine colon cancer in vivo: enhancement of immune response to radiotherapy and potential as a radiosensitizer. (PubMed, Transl Cancer Res)
    In the second FCM series, the mean Treg proportion and Teff/Treg ratio in the 0 mg + RT and 30 mg + RT groups were 4.0% and 1.5%, respectively (P=0.04) and 10 and 22, respectively (P=0.04). AAT-008 potentially enhances the radiosensitivity of colon cancer cells, apparently by stimulating the immune system against the cancer cells.
    Preclinical • Journal
    |
    CD69 (CD69 Molecule)
    |
    AAT-008
    4years
    Biological Effects of Prostagrandin E2-EP4 Antagonist (AAT-008): Enhancement of Immunoresponse to Radiotherapy and a Potential as a Radiosensitizer. (PubMed, Int J Radiat Oncol Biol Phys)
    AAT-008 had a potential of enhancing radiosensitivity in the treatment of colon cancer cells. It was assumed that the optimal dose of AAT-008 with RT was 10 mg/kg/day. It was suggested that AAT-008 stimulated the immune system against the cancer cells.
    Journal
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • FOXP3 (Forkhead Box P3)
    |
    AAT-008